Monday, January 18, 2021

01 Communique Announces Bounty Contest 2021 Exclusively Sponsored by PwC China

One:Tsx-v New 2021 Contest



TORONTO, ON / ACCESSWIRE / January 18, 2021 / 01 Communique Laboratory Inc. (TSXV:ONE)(OTCQB:OONEF) (the “Company”) one of the first-to-market, enterprise level cybersecurity providers for the quantum computing era, today announced a Bounty Contest. You are invited to join the Bounty Contest 2021 (February 22 - March 22) for the chance to win a grand prize of CAD100,000 in cash. This Bounty Contest is exclusively sponsored by PwC China.

As the race for quantum supremacy intensifies, so is the concern over cyber security. Quantum computers could very well crack traditional encryption earlier than we expect. Canadian Company 01 Communique claims that its cryptography technology, IronCAP™ can be deployed on existing computers in order to protect them against the quantum threat. It is prepared to put IronCAP™ to the test in the Bounty Contest.

Andrew Cheung enthusiastically stated, “This Bounty Contest is an ideal platform for participants who are innovators, researchers, scientists, domain experts, academics to test our IronCAP™ technology. I am confident that IronCAP™ can face these challenges and ultimately earn recognition as the best-in-class quantum safe solution. Having PwC China’s support in this important exercise is of particular significance given China’s advanced research and development capability in Quantum technology.”

Samuel Sinn, Partner, Cybersecurity & Privacy Services, PwC China stated: “We are delighted to sponsor this Bounty Contest organized by 01 Communique Laboratory Inc. We rely on encryption technology to protect our information asset, and as we approach the Quantum age, we need a new generation of cryptographic solutions to continue to safeguard the trust we need in the digital world. This contest is an excellent opportunity for IronCAP™ to demonstrate its robustness against the quantum threat.”

Details:

The Company expects participants from around the world to test its quantum-safe encryption. Beginning on Monday, February 22 at 12am EST, participants will be given 30 days to explore IronCAP™ encryption. A cash prize of CAD100,000 will be awarded to the first person that is able to break the encryption. The result will be announced on Monday, March 22 where the outcome of the Bounty Contest will be revealed!

You can register for the event beginning February 8th online at https://ironcap.ca/ironcap-bountycontest.

About IronCAP™ and IronCAP X™:

IronCAP™ is at the forefront of the cyber security market and is designed to protect our customers from cyber-attacks. IronCAP’s patent-pending cryptographic system is designed to protect users and enterprises against the ever-evolving illegitimate and malicious means of gaining access to their data today as well as in the future with the introduction of powerful quantum computers. Based on improved Goppa code-based encryption it is designed to be faster and more secure than current standards. It operates on conventional computer systems, so users are protected today while being secure enough to safeguard against future attacks from the world of quantum computers. An IronCAP™ API is available which allows vendors of a wide variety of vertical applications to easily transform their products to ensure their customers are safe from cyber-attacks today and from quantum computers in the future.


IronCAP X™, a cybersecurity product for email/file encryption, incorporating our patent-pending technology for commercial. The new product has two major differentiations from what is in the market today. Firstly, many offerings in today’s market store users secured emails on email-servers for recipients to read, making email-servers a central target of cyber-attack. IronCAP X™, on the other hand, delivers each encrypted message end-to-end to the recipients such that only the intended recipients can decrypt and read the message. Consumers’ individual messages are protected, eliminating the hackers’ incentive to attack email servers of email providers. Secondly, powered by our patent-pending IronCAP™ technology, we believe IronCAP X™ is the world’s first quantum-safe end-to-end email encryption system; secured against cyberattacks from today’s systems and from quantum computers in the future. Consumers and businesses using IronCAP X™ will be protected by tomorrow’s cybersecurity today.

About 01 Communique

Established in 1992, 01 Communique (TSX-V: ONE; OTCQB: OONEF) has always been at the forefront of technology. The Company’s cyber security business unit focuses on post-quantum cybersecurity with the development of its IronCAP™ technology. IronCAP’s patent-pending cryptographic system is an advanced Goppa code-based post-quantum cryptographic technology that can be implemented on classical computer systems as we know them today while at the same time can also safeguard against attacks in the future post-quantum world of computing. 

The Company’s remote access business unit provides its customers with a suite of secure remote access services and products under its I’m InTouch and I’m OnCall product offerings. 

The remote access offerings are protected in the U.S.A. by its patents #6,928,479 / #6,938,076 / #8,234,701; in Canada by its patents #2,309,398 / #2,524,039 and in Japan by its patent #4,875,094. For more information, visit the Company’s web site at www.ironcap.ca and www.01com.com.


Cautionary Note Regarding Forward-looking Statements

Certain statements in this news release may constitute “forward-looking” statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. When used in this news release, such statements use such words as “may”, “will”, “expect”, “believe”, “anticipate”, “plan”, “intend”, “are confident” and other similar terminology. Such statements include statements regarding the business prospects of IronCAP™ and IronCAP X™, the future of quantum computers and their impact on the Company’s product offering, the functionality of the Company’s products and the intended product lines for the Company’s technology. These statements reflect current expectations regarding future events and operating performance and speak only as of the date of this news release. Forward-looking statements involve significant risks and uncertainties, should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether or not such results will be achieved. A number of factors could cause actual results to differ materially from the matters discussed in the forward-looking statements, including, but not limited to, a delay in the anticipated adoption of quantum computers and a corresponding delay in Q day, the ability for the Company to generate sales, and gain adoption of, IronCAP™ and IronCAP X™, the ability of the Company to raise financing to pursue its business plan, competing products that provide a superior product, competitors with greater resources and the factors discussed under “Risk and Uncertainties” in the company’s Management`s Discussion and Analysis document filed on SEDAR. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions, the company cannot assure investors that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this news release, and the company assumes no obligation to update or revise them to reflect new events or circumstances.


Neither TSX Venture Exchange (“TSX-V”) nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

INVESTOR CONTACT:

Brian Stringer

Chief Financial Officer

01 Communique

(905) 795-2888 x204

SOURCE: 01 Communique Laboratory, Inc.



Monday, December 7, 2020

Empower Clinics Inc. (CBDT.CN)

 


House Positions for C:CBDT from 20201207 to 20201207
HouseBought$ValAveSold$ValAveNet$Net
2 RBC7,147,7161,423,7600.1994,202,732888,9520.2122,944,984-534,808
7 TD Sec9,609,6041,923,8290.207,949,3361,629,6250.2051,660,268-294,204
79 CIBC4,176,016840,2300.2012,663,634550,3550.2071,512,382-289,875
9 BMO Nesbitt4,952,8581,067,9270.2163,451,248666,6780.1931,501,610-401,249
89 Raymond James1,038,174204,2150.197117,44123,0610.196920,733-181,154
85 Scotia2,888,766553,2240.1921,987,707402,2000.202901,059-151,024
124 Questrade2,247,465461,5850.2051,373,970280,1450.204873,495-181,440
88 Credential1,534,872349,9260.228896,819206,4710.23638,053-143,455
19 Desjardins935,267174,9780.187717,504135,5240.189217,763-39,454
25 Odlum100,00021,5000.2150100,000-21,500
39 Merrill Lynch91,25318,1110.19818,0513,5440.19673,202-14,567
212 Virtu1,8723960.21210,9142,2040.202-9,0421,808
68 Leede050,00010,0000.20-50,00010,000
28 BBS050,50110,6940.212-50,50110,694
80 National Bank595,994126,1960.212647,751137,1360.212-51,75710,940
76 Industrial Alliance055,80012,6600.227-55,80012,660
36 Latimer17,7913,8410.21679,99816,1670.202-62,20712,326
33 Canaccord2,113,000403,6250.1912,197,300430,6590.196-84,30027,034
62 Haywood13,0502,8710.22165,00037,9600.23-151,95035,089
59 PI75,00015,7500.21470,59191,8720.195-395,59176,122
83 Mackie130,00028,0100.2152,000,000335,2270.168-1,870,000307,217
13 Instinet1,147,000240,1250.2093,057,000633,4460.207-1,910,000393,321
1 Anonymous11,533,8502,321,5120.20118,186,2513,677,0280.202-6,652,4011,355,516
TOTAL50,349,54810,181,6110.20250,349,54810,181,6080.2020-3

Wednesday, December 2, 2020

Appili doses first participant in phase 3 Avigan trial



2020-12-02 09:32 ET - News Release

Dr. Armand Balboni reports

FIRST PATIENT DOSED IN APPILI THERAPEUTICS' PHASE 3 CLINICAL TRIAL OF AVIGAN TABLETS (FAVIPIRAVIR) FOR THE TREATMENT OF COVID-19 IN THE UNITED STATES

Appili Therapeutics Inc.'s investigators have dosed the first participant in its phase 3 trial (referred to as the PRESECO clinical trial) evaluating oral Avigan tablets (favipiravir) for the treatment of COVID-19. Appili has engaged PRA Health Sciences as a clinical research organization to administer the trial at 47 outpatient sites. The randomized, double-blind, placebo-controlled study will enroll approximately 826 participants. This study is the second Appili-sponsored COVID-19 clinical trial that has initiated dosing this quarter. Appili expects to report early data from the PRESECO study in the first half of 2021. Appili is initially focusing the trial in the United States but may expand the program to other areas of the world affected by COVID-19.

"Dosing the first participants in our first phase 3 trial is a significant milestone as we work to stem the tide of this coronavirus," said Dr. Yoav Golan, chief medical officer, Appili Therapeutics. "Early intervention with patients before they develop severe COVID-19 and require hospitalization remains a significant unmet need in the COVID-19 treatment landscape. As is the case with influenza, we believe that even with effective vaccines, oral anti-virals will play a critical role in treating COVID-19 and preventing its progression. Avigan's pill format and shelf-life stability make it particularly well suited for this endeavour and we look forward to gathering the necessary data to determine Avigan's utility for these patients."

Appili's COVID-19 Clinical Program

Appili is sponsoring three randomized, double-blind, placebo-controlled clinical studies to determine the safety and effectiveness of Avigan tablets in outpatients in multiple COVID-19 indications:

  • The phase 3 PRESECO (preventing severe COVID disease) study aims to determine the efficacy of Avigan as a treatment for COVID-19 in patients with a positive COVID-19 test and mild-to-moderate symptoms, with the goal of alleviating symptoms and preventing disease progression before the infection requires hospitalizations or other intensive interventions;
  • The phase 3 PEPCO (postexposure prophylaxis for COVID-19) study is evaluating Avigan in preventing the development of COVID-19 when given to asymptomatic individuals who have had direct exposure (within 72 hours) to an infected person; and
  • The phase 2 CONTROL study is evaluating the use of Avigan to control outbreaks of COVID-19 in Canadian long-term care facilities, where the burden of severe disease and death is unusually high.

"We are fully committed to obtaining robust clinical data that demonstrates how Avigan may best fit into the full spectrum of a global pandemic response by addressing significant unmet needs," said Dr. Armand Balboni, chief executive officer, Appili Therapeutics. "Providing early access to anti-viral therapy is the cornerstone of our clinical strategy. Working with regulatory agencies and our partners, we have chosen to pursue a multipronged clinical trial approach, with triggers for treatment that include either a positive COVID diagnosis or known recent exposure to a COVID-19 case. Our target patient population includes those in the outpatient setting most vulnerable to the devastating effects of advanced COVID-19 infections, including those over 50, with significant co-morbidities, and front-line workers."

About Avigan (favipiravir)

Avigan is a broad-spectrum anti-viral in oral tablet form developed by FUJIFILM Toyama Chemical Co. Ltd. (FFTC) and approved in Japan as a treatment and stockpile countermeasure for pandemic influenza. Following promising clinical studies, Russia and India recently approved favipiravir-based anti-viral medications for the emergency treatment of COVID-19. FFTC recently announced positive phase 3 data in the use of Avigan in hospitalized COVID-19 patients.

Unlike most other interventions that researchers are evaluating in COVID-19, Avigan has already been thoroughly studied in human trials and has a well-known safety profile, with over 3,000 subjects receiving at least one dose of the drug. Avigan's oral tablet form is shelf-stable and has an established commercial manufacturing process, which may provide advantages over other COVID-19 interventions, which often require temperature-controlled storage and/or injection or intravenous administration.

Appili has joined a consortium of companies, including Dr. Reddy's Labs, Global Response Aid and FFTC, for the worldwide development and distribution of Avigan tablets for the potential treatment and prevention of COVID-19 (excluding Japan, China and Russia). This consortium is designed to ensure that Avigan is thoroughly evaluated in rigorous clinical studies and, if it receives the proper regulatory approvals, has the infrastructure in place to support worldwide distribution.

About Appili Therapeutics Inc.

Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili's goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. As part of a global consortium, Appili is sponsoring late-stage clinical trials evaluating the anti-viral Avigan (favipiravir) for the worldwide treatment and prevention of COVID-19. The company is also advancing a diverse range of anti-infectives, including a broad-spectrum anti-fungal, a vaccine candidate to eliminate a serious biological weapon threat, and two novel antibiotic programs. Led by a proven management team, Appili is at the epicentre of the global fight against infection.

We seek Safe Harbor.

© 2020 Canjex Publishing Ltd. All rights reserved.

01 Communique releases 2021-2025 business plan


 


01 Communique releases 2021-2025 business plan

2020-11-16 16:24 ET - News Release

Mr. Andrew Cheung reports

01 COMMUNIQUE ANNOUNCES STRATEGIC GROWTH PLAN

01 Communique Inc. has released some of the key initiatives in its fiscal 2021 to 2025 business plan. The plan is designed to achieve growth in revenues and earnings. As support for the company's plan, the company has already secured major new global enterprise partners to help achieve its objectives and expects to add more new partners throughout fiscal 2021 and beyond.

As previously announced, the company will host a live webcast on Nov. 17 at 11 a.m. ET to discuss details of the plan. Investors are invited to register in advance for the live webcast of the call and investor presentation on the company's website.

Andrew Cheung, president and chief executive officer of 01 Communique, commented: "Q-Day, the day quantum computers are expected to render current encryption methods meaningless, is coming. 01 Communique has developed what we believe to be the first-to-market enterprise-level cybersecurity software for the quantum computing era. Our patent-pending, proprietary, quantum-safe cybersecurity products IronCAP and IronCAP X are expected to drive revenue growth. IronCAP, which was uncrackable during a month-long hack-a-thon last year, is expected to enable us to generate significant revenue as we grow our global client base."

Under Mr. Cheung's leadership and an exceptionally talented research and development team led by Sergey Strakhov as chief technology officer and Prof. Bezzateev as crypto scientist, 01 Communique has developed a variety of software-as-a-service technologies over the past 20 years. In addition to IronCAP X, revenue-generating products include I'm InTouch remote access software and I'm OnCall remote support. Revenue from these two products has helped the company finance the development of IronCAP X.

Mr. Cheung stated: "Now we are launching our game-changing, enterprise-level IronCAP X quantum-safe cybersecurity product to the global market. Over the next few years, we expect to invest in our infrastructure to support the growth of our business."

Key investment highlights

The company is providing its key investment highlights, which have been outlined in a presentation that will be available shortly after tomorrow's webcast on the company's website.

The company is:

  • Serving a massive global encryption software market forecasted to grow from $600-million (U.S.) in 2018 to $1.7-billion (U.S.) in 2024, representing a CAGR (compound annual growth rate) of 18.7 per cent (1);
  • Targeting global postquantum cryptograph vertical markets, which include e-mail encryption, file storage, website protection and financial transactions;
  • Planning to launch IronCAP X enterprise version in first quarter 2021 (2) with world-class early-adopter partners;
  • One of the first to market with proprietary, patent-pending, enterprise software for the quantum computing era that the company believes has the potential to become the de facto solution globally;
  • A disruptive cybersecurity SaaS company with an aggressive plan to generate increased revenue and net income margin growth;
  • At a financial inflection point which provides an attractive investment entry point, Q-day represents a massive potential catalyst for investors.

Strategic growth plan

The plan is designed to achieve growth in revenues and earnings. Revenue growth is expected to be driven by being one of the first to market with quantum-safe encryption technology, which the company anticipates will enable it to rapidly add new enterprise customers. It will be supported by free IronCAP X licences to individuals, which are expected to accelerate adoption of the technology.

The company's goal is to become the de facto solution globally for quantum-safe encryption. The advent of quantum computers has implications for every electronic communication, file storage, website and financial transaction as Q-day is expected to render current encryption methods meaningless.

Over the next few years, the company expects to make significant investments in company infrastructure. This includes not only marketing, sales and business development, but also R&D, finance and business processes. The company expects these investments to support the growth of the business, thereby enabling significant future levels of profitability.

About 01 Communique Inc.

Established in 1992, 01 Communique has always been at the forefront of technology. The company's cybersecurity business unit focuses on postquantum cybersecurity with the development of its IronCAP technology. IronCAP's patent-pending cryptographic system is an advanced Goppa-code-based postquantum cryptographic technology that can be implemented on classical computer systems as known today and at the same time can also safeguard against attacks in the future postquantum world of computing. The company's remote access business unit provides its customers with a suite of secure remote access services and products under its I'm InTouch and I'm OnCall product offerings. The remote access offerings are protected in the United States by its patents No. 6,928,479/No. 6,938,076/No. 8,234,701; in Canada by its patents No. 2,309,398/No. 2,524,039 and in Japan by its patent No. 4,875,094.

(1) Gartner Forecast Analysis: Information Security and Risk Management, Worldwide, report -- July, 2020.

(2) IronCAP and IronCAP X, a new cybersecurity product for e-mail/file encryption, incorporating patent-pending technology, was made available for commercial use on April 23, 2020. The enterprise version is expected to be available in first quarter 2021.

We seek Safe Harbor.

© 2020 Canjex Publishing Ltd. All rights reserved.